Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK

Lignende værker

• Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
  af: William Y. K. Hwang, et al.
  Udgivet: (2009-01-01)
• Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients
  af: Marco Montillo, et al.
  Udgivet: (2014-09-01)
• Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
  af: M Hoyle, et al.
  Udgivet: (2011-05-01)
• Individual features of the pharmacokinetics of fludarabin phosphate in the treatment of patients with chronic lymphocytic leukemia
  af: G. G. Rodionov, et al.
  Udgivet: (2021-08-01)
• Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy
  af: Ester M. Orlandi, et al.
  Udgivet: (2008-11-01)